Related Experiment Video
Updated: May 12, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma
Stephen R Goding1, Kyle A Wilson, Ying Xie
1Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Abstract:
Recurrent solid malignancies are often refractory to standard therapies. Although adoptive T cell transfer may benefit select individuals, the majority of patients succumb to their disease. To address this important clinical dilemma, we developed a mouse melanoma model in which initial regression of advanced disease was followed by tumor recurrence. During recurrence, Foxp3(+) tumor-specific CD4(+) T cells became PD-1(+) and represented >60% of the tumor-specific CD4(+) T cells in the host. Concomitantly, tumor-specific CD4(+) T effector cells showed traits of chronic exhaustion, as evidenced by their high expression of the PD-1, TIM-3, 2B4, TIGIT, and LAG-3 inhibitory molecules. Although blockade of the PD-1/PD-L1 pathway with anti-PD-L1 Abs or depletion of tumor-specific regulatory T cells (Tregs) alone failed to reverse tumor recurrence, the combination of PD-L1 blockade with tumor-specific Treg depletion effectively mediated disease regression. Furthermore, blockade with a combination of anti-PD-L1 and anti-LAG-3 Abs overcame the requirement to deplete tumor-specific Tregs. In contrast, successful treatment of primary melanoma with adoptive cell therapy required only Treg depletion or Ab therapy, underscoring the differences in the characteristics of treatment between primary and relapsing cancer. These data highlight the need for preclinical development of combined immunotherapy approaches specifically targeting recurrent disease.
Insights
Combination immunotherapies targeting PD-L1 and LAG-3 show promise for treating recurrent melanoma. These approaches overcome tumor resistance and T cell exhaustion, offering new hope for refractory solid malignancies.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Recurrent solid tumors are difficult to treat with standard therapies.
- Adoptive T cell transfer benefits only a few patients with advanced cancer.
- Tumor recurrence is a major challenge in cancer treatment, often associated with immune evasion.
Purpose of the Study:
- To investigate novel immunotherapy strategies for recurrent melanoma.
- To understand the immune landscape of recurrent melanoma.
- To identify effective combination therapies for refractory cancers.
Main Methods:
- Developed a mouse melanoma model with tumor recurrence.
- Analyzed T cell exhaustion markers (PD-1, TIM-3, 2B4, TIGIT, LAG-3) in recurrent tumors.
- Tested combination therapies including anti-PD-L1 antibodies and regulatory T cell (Treg) depletion.
Main Results:
- Recurrent melanoma exhibited exhausted tumor-specific CD4+ T cells expressing PD-1 and other inhibitory molecules.
- Single-agent therapies (anti-PD-L1 or Treg depletion) failed to reverse recurrence.
- Combination of PD-L1 blockade and Treg depletion, or combined anti-PD-L1/anti-LAG-3 blockade, effectively mediated tumor regression.
- Treatment strategies differed significantly between primary and recurrent melanoma.
Conclusions:
- Combined immunotherapy approaches are crucial for overcoming resistance in recurrent melanoma.
- Targeting T cell exhaustion and regulatory T cells offers a promising strategy for refractory cancers.
- Preclinical development of combination immunotherapies is needed for recurrent malignancies.
Related Concept Videos
01:27Tumor Immunotherapy
01:40Cell-mediated Immune Responses